Pharmaceutical industry leaders are calling executive orders from the White House that aim to restructure the prescription drug market short-sighted and claim the changes will cripple innovation and could hinder the industry’s response to the novel coronavirus.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,